Nasdaq
$30.99▼ 0.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.58BShares out 50.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.7Regular26.10.08 00:47SCHEDULE 13G/AOwnership#●●●#●●●
Immunocore Holdings plc
FMR LLC, its affiliates, and Abigail P. Johnson have filed a Schedule 13G regarding their beneficial ownership of Immunocore Holdings plc common stock. This filing reflects the share ownership status as of September 30, 2026, and includes a joint filing agreement among the FMR reporters.…more
$30.99-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14Pre-market26.09.14 20:158-KKey event
Immunocore Holdings plc
Immunocore has achieved its target enrollment of 540 patients for the Phase 3 TEBE-AM clinical trial. The study evaluates KIMMTRAK as a monotherapy and in combination with pembrolizumab for advanced melanoma, with topline overall survival data expected as early as the end of 2026.…more
$30.99-0.24%vs prev closeView filingShare - 8.6Regular26.08.06 23:28SCHEDULE 13G/AOwnership
Immunocore Holdings plc
FMR LLC와 그 계열사들이 2026년 6월 30일 기준 이뮤노코어 홀딩스(Immunocore Holdings plc)의 보통주 지분을 5% 이상 보유하고 있음을 공시했습니다. 이번 공시는 FMR LLC와 애비게일 P. 존슨을 포함한 주요 주주들의 지분 보유 현황 및 의결권 행사 구조를 명시한 대량보유 보고서입니다.…more
$30.99-0.24%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Pre-market26.09.14 20:01#●●●#●●●
Immunocore Completes Target Enrollment for Phase 3 Melanoma Trial
Immunocore has successfully enrolled 540 patients in its global Phase 3 clinical trial for KIMMTRAK in advanced melanoma. Topline overall survival data from the study is expected to be released as early as the end of 2026.…more
$30.99-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.1Pre-market26.09.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Immunocore announced that its management will participate in several global healthcare investor conferences throughout September. This is a routine corporate event announcement and does not provide new material information affecting the stock price.…more
$30.99-0.24%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report